Table 1.
Patient characteristics at inclusion in the validation study
| Mild (N = 132) | Moderate (N = 166) | Severe (N = 132) | Inclusion population (N = 430) | |
|---|---|---|---|---|
| Age (years) | ||||
| Mean (SD) | 48.0 (14.6) | 46.7 (13.6) | 45.1 (14.9) | 46.6 (14.3) |
| Min–Max | 18.0–82.0 | 19.0–81.0 | 19.0–83.0 | 18.0–83.0 |
| Gender (%) | ||||
| Males | 59.1 | 58.4 | 64.4 | 60.5 |
| Time since diagnosis (years) | ||||
| Mean (SD) | 18.6 (14.8) | 17.2 (12.5) | 18.1 (12.2) | 17.9 (13.1) |
| Min–Max | 0.0–74.0 | 0.0–52.0 | 0.0–54.0 | 0.0–74.0 |
| First psoriasis episode (%) | ||||
| Yes | 5.3 | 3.0 | 4.5 | 4.2 |
| Current psoriasis flare (%) | ||||
| Yes | 40.9 | 76.5 | 74.2 | 64.9 |
| Psoriatic arthritis (%) | ||||
| Yes | 21.2 | 19.9 | 32.6 | 24.2 |
| No treatment (%) | 3.0 | 7.8 | 4.5 | 5.3 |
| Topical treatment (alone) (%) | 32.6 | 19.9 | 21.2 | 24.2 |
| Topical + phototherapies (%) | 1.5 | 7.8 | 4.6 | 4.9 |
| Topical + systemic (%) | 5.3 | 13.3 | 12.9 | 10.7 |
| Topical + biotherapies (%) | 9.1 | 6.0 | 15.9 | 10.0 |
| Topical + others (%) | – | 0.6 | – | 0.2 |
| Topical + phototherapies + systemic (%) | – | – | 0.8 | 0.2 |
| Topical + phototherapies + others (%) | – | 0.6 | – | 0.2 |
| Topical + systemic + biotherapies (%) | – | – | 0.8 | 0.2 |
| Phototherapies (alone) (%) | 0.0 | 3.0 | 3.8 | 2.3 |
| Phototherapies + systemic (%) | – | 0.6 | – | 0.2 |
| Phototherapies + others (%) | – | 0.6 | – | 0.2 |
| Systemic medications (alone) (%) | 10.6 | 17.5 | 8.3 | 12.6 |
| Systemic + biotherapies (%) | 2.3 | 0.6 | 0.8 | 1.2 |
| Systemic + others (%) | 0.8 | – | – | 0.2 |
| Biotherapies (alone) (%) | 32.6 | 20.5 | 23.5 | 25.1 |
| Others (alone) (%) | 2.3 | 1.2 | 3.0 | 2.1 |